{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:00:57Z","timestamp":1790492457442,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-03648-3","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T18:46:23Z","timestamp":1765565183000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["MYBL2 regulates the expression of CENPF in lung adenocarcinoma and promotes tumor development and metastasis through AKT pathway activation"],"prefix":"10.1186","volume":"31","author":[{"given":"Yan","family":"liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuyang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"issue":"2","key":"3648_CR1","first-page":"69","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69\u201390.","journal-title":"CA Cancer J Clin"},{"key":"3648_CR2","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.12433.1","volume":"7","author":"M New","year":"2018","unstructured":"New M, Keith R. Early detection and chemoprevention of lung cancer. F1000Res. 2018;7:61.","journal-title":"F1000Res"},{"issue":"3","key":"3648_CR3","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3648_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106656","volume":"188","author":"Y Peng","year":"2023","unstructured":"Peng Y, Zhang W, Chen Y, et al. Engineering c-Met-CAR NK-92 cells as a promising therapeutic candidate for lung adenocarcinoma. Pharmacol Res. 2023;188:106656.","journal-title":"Pharmacol Res"},{"issue":"2","key":"3648_CR5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2174\/1874467215666220329212300","volume":"16","author":"Y Cai","year":"2023","unstructured":"Cai Y, Sheng Z, Dong Z, et al. EGFR inhibitor CL-387785 suppresses the progression of lung adenocarcinoma. Curr Mol Pharmacol. 2023;16(2):211\u20136.","journal-title":"Curr Mol Pharmacol"},{"issue":"9","key":"3648_CR6","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/cam4.479","volume":"4","author":"SE Schild","year":"2015","unstructured":"Schild SE, Tan AD, Wampfler JA, et al. A new scoring system for predicting survival in patients with non-small cell lung cancer. Cancer Med. 2015;4(9):1334\u201343.","journal-title":"Cancer Med"},{"issue":"5","key":"3648_CR7","doi-asserted-by":"publisher","first-page":"e278S","DOI":"10.1378\/chest.12-2359","volume":"143","author":"JA Howington","year":"2013","unstructured":"Howington JA, Blum MG, Chang AC, et al. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5):e278S-e313S.","journal-title":"Chest"},{"issue":"2","key":"3648_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.devcel.2004.12.015","volume":"8","author":"ML Sandberg","year":"2005","unstructured":"Sandberg ML, Sutton SE, Pletcher MT, et al. c-Myb and p300 regulate hematopoietic stem cell proliferation and differentiation. Dev Cell. 2005;8(2):153\u201366.","journal-title":"Dev Cell"},{"key":"3648_CR9","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00825","volume":"2","author":"S Heinrichs","year":"2013","unstructured":"Heinrichs S, Conover LF, Bueso-Ramos CE, et al. MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy. Elife. 2013;2:e825.","journal-title":"Elife"},{"issue":"7","key":"3648_CR10","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1080\/15548627.2015.1040970","volume":"11","author":"J Yuan","year":"2015","unstructured":"Yuan J, Zhang Y, Sheng Y, et al. MYBL2 guides autophagy suppressor VDAC2 in the developing ovary to inhibit autophagy through a complex of VDAC2-BECN1-BCL2L1 in mammals. Autophagy. 2015;11(7):1081\u201398.","journal-title":"Autophagy"},{"issue":"6","key":"3648_CR11","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/j.celrep.2018.07.026","volume":"24","author":"C Ward","year":"2018","unstructured":"Ward C, Volpe G, Cauchy P, et al. Fine-tuning Mybl2 is required for proper mesenchymal-to-epithelial transition during somatic reprogramming. Cell Rep. 2018;24(6):1496\u2013511.","journal-title":"Cell Rep"},{"issue":"10","key":"3648_CR12","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/stem.496","volume":"28","author":"M Lorvellec","year":"2010","unstructured":"Lorvellec M, Dumon S, Maya-Mendoza A, et al. B-Myb is critical for proper DNA duplication during an unperturbed S phase in mouse embryonic stem cells. Stem Cells. 2010;28(10):1751\u20139.","journal-title":"Stem Cells"},{"issue":"3","key":"3648_CR13","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s10549-011-1826-2","volume":"131","author":"H Shi","year":"2012","unstructured":"Shi H, Bevier M, Johansson R, et al. Prognostic impact of polymorphisms in the MYBL2 interacting genes in breast cancer. Breast Cancer Res Treat. 2012;131(3):1039\u201347.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"3648_CR14","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/leu.2012.241","volume":"27","author":"M Clarke","year":"2013","unstructured":"Clarke M, Dumon S, Ward C, et al. MYBL2 haploinsufficiency increases susceptibility to age-related haematopoietic neoplasia. Leukemia. 2013;27(3):661\u201370.","journal-title":"Leukemia"},{"issue":"5","key":"3648_CR15","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/his.13281","volume":"71","author":"K Fujii","year":"2017","unstructured":"Fujii K, Murase T, Beppu S, et al. MYB, MYBL1, MYBL2 and NFIB gene alterations and MYC overexpression in salivary gland adenoid cystic carcinoma. Histopathology. 2017;71(5):823\u201334.","journal-title":"Histopathology"},{"issue":"5","key":"3648_CR16","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1159\/000475454","volume":"41","author":"HB Liang","year":"2017","unstructured":"Liang HB, Cao Y, Ma Q, et al. MYBL2 is a potential prognostic marker that promotes cell proliferation in gallbladder cancer. Cell Physiol Biochem. 2017;41(5):2117\u201331.","journal-title":"Cell Physiol Biochem"},{"issue":"6","key":"3648_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.244","volume":"8","author":"J Musa","year":"2017","unstructured":"Musa J, Aynaud MM, Mirabeau O, et al. MYBL2 (B-Myb): a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis. Cell Death Dis. 2017;8(6):e2895.","journal-title":"Cell Death Dis"},{"issue":"3","key":"3648_CR18","first-page":"4832","volume":"17","author":"M Shao","year":"2018","unstructured":"Shao M, Ren Z, Zhang R. MYBL2 protects against H9c2 injury induced by hypoxia via AKT and NF\u2011kappaB pathways. Mol Med Rep. 2018;17(3):4832\u20138.","journal-title":"Mol Med Rep"},{"key":"3648_CR19","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.2147\/OTT.S188820","volume":"12","author":"Y Jia","year":"2019","unstructured":"Jia Y, Gao Y, Li J, et al. Prognostic implications of MYBL2 in resected Chinese gastric adenocarcinoma patients. Onco Targets Ther. 2019;12:1129\u201335.","journal-title":"Onco Targets Ther"},{"issue":"22","key":"3648_CR20","doi-asserted-by":"publisher","first-page":"3927","DOI":"10.1038\/sj.emboj.7600848","volume":"24","author":"P Bomont","year":"2005","unstructured":"Bomont P, Maddox P, Shah JV, et al. Unstable microtubule capture at kinetochores depleted of the centromere-associated protein CENP-F. EMBO J. 2005;24(22):3927\u201339.","journal-title":"EMBO J"},{"issue":"4","key":"3648_CR21","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s00412-005-0046-0","volume":"115","author":"A Varis","year":"2006","unstructured":"Varis A, Salmela AL, Kallio MJ. Cenp-F (mitosin) is more than a mitotic marker. Chromosoma. 2006;115(4):288\u201395.","journal-title":"Chromosoma"},{"issue":"3","key":"3648_CR22","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1083\/jcb.130.3.507","volume":"130","author":"H Liao","year":"1995","unstructured":"Liao H, Winkfein RJ, Mack G, et al. CENP-F is a protein of the nuclear matrix that assembles onto kinetochores at late G2 and is rapidly degraded after mitosis. J Cell Biol. 1995;130(3):507\u201318.","journal-title":"J Cell Biol"},{"issue":"2","key":"3648_CR23","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/nprot.2006.106","volume":"1","author":"AA Margolin","year":"2006","unstructured":"Margolin AA, Wang K, Lim WK, et al. Reverse engineering cellular networks. Nat Protoc. 2006;1(2):662\u201371.","journal-title":"Nat Protoc"},{"issue":"3","key":"3648_CR24","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/cm.970260305","volume":"26","author":"JB Rattner","year":"1993","unstructured":"Rattner JB, Rao A, Fritzler MJ, et al. CENP-F is a .ca 400 kDa kinetochore protein that exhibits a cell-cycle dependent localization. Cell Motil Cytoskeleton. 1993;26(3):214\u201326.","journal-title":"Cell Motil Cytoskeleton"},{"issue":"5","key":"3648_CR25","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ccr.2014.03.017","volume":"25","author":"A Aytes","year":"2014","unstructured":"Aytes A, Mitrofanova A, Lefebvre C, et al. Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer Cell. 2014;25(5):638\u201351.","journal-title":"Cancer Cell"},{"issue":"2","key":"3648_CR26","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.18632\/aging.202303","volume":"13","author":"T Hexiao","year":"2021","unstructured":"Hexiao T, Yuquan B, Lecai X, et al. Knockdown of CENPF inhibits the progression of lung adenocarcinoma mediated by ERbeta2\/5 pathway. Aging (Albany NY). 2021;13(2):2604\u201325.","journal-title":"Aging (Albany NY)"},{"issue":"35","key":"3648_CR27","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.2174\/092986710793361234","volume":"17","author":"P Wu","year":"2010","unstructured":"Wu P, Hu YZ. PI3K\/Akt\/mTOR pathway inhibitors in cancer: a perspective on clinical progress. Curr Med Chem. 2010;17(35):4326\u201341.","journal-title":"Curr Med Chem"},{"issue":"4","key":"3648_CR28","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s00280-012-2043-3","volume":"71","author":"HR Burris","year":"2013","unstructured":"Burris HR. Overcoming acquired resistance to anticancer therapy: focus on the PI3K\/AKT\/mTOR pathway. Cancer Chemother Pharmacol. 2013;71(4):829\u201342.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"3648_CR29","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.bcp.2014.05.011","volume":"90","author":"C Fumarola","year":"2014","unstructured":"Fumarola C, Bonelli MA, Petronini PG, et al. Targeting PI3K\/AKT\/mTOR pathway in non small cell lung cancer. Biochem Pharmacol. 2014;90(3):197\u2013207.","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"3648_CR30","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/odi.12206","volume":"21","author":"BR Vander","year":"2015","unstructured":"Vander BR, Mohan S, Eytan DF, et al. The PI3K\/Akt\/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies. Oral Dis. 2015;21(7):815\u201325.","journal-title":"Oral Dis"},{"issue":"11","key":"3648_CR31","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/neuonc\/noz105","volume":"21","author":"FM Ippen","year":"2019","unstructured":"Ippen FM, Grosch JK, Subramanian M, et al. Targeting the PI3K\/Akt\/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases. Neuro Oncol. 2019;21(11):1401\u201311.","journal-title":"Neuro Oncol"},{"key":"3648_CR32","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.semcancer.2021.06.019","volume":"85","author":"L Yu","year":"2022","unstructured":"Yu L, Wei J, Liu P. Attacking the PI3K\/Akt\/mTOR signaling pathway for targeted therapeutic treatment in human cancer. Semin Cancer Biol. 2022;85:69\u201394.","journal-title":"Semin Cancer Biol"},{"key":"3648_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2024.101005","volume":"25","author":"H Liao","year":"2024","unstructured":"Liao H, Cao Y, Hu C, et al. Oxygen-producing and pH-responsive targeted DNA nanoflowers for enhanced chemo-sonodynamic therapy of lung cancer. Mater Today Bio. 2024;25:101005.","journal-title":"Mater Today Bio"},{"key":"3648_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2024.100997","volume":"25","author":"AS Joshi","year":"2024","unstructured":"Joshi AS, Bapat MV, Singh P, et al. Viridibacillus culture derived silver nanoparticles exert potent anticancer action in 2D and 3D models of lung cancer via mitochondrial depolarization-mediated apoptosis. Mater Today Bio. 2024;25:100997.","journal-title":"Mater Today Bio"},{"issue":"1-2","key":"3648_CR35","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s11010-020-03721-x","volume":"468","author":"YC Xiong","year":"2020","unstructured":"Xiong YC, Wang J, Cheng Y, et al. Overexpression of MYBL2 promotes proliferation and migration of non-small-cell lung cancer via upregulating NCAPH. Mol Cell Biochem. 2020;468(1\u20132):185\u201393.","journal-title":"Mol Cell Biochem"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03648-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-03648-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03648-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T18:05:15Z","timestamp":1768845915000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40001-025-03648-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3648"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-03648-3","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent for participation"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"92"}}